Innate Immunotherapeutics Ltd
* Results for trial of MIS416 in patients with secondary progressive multiple sclerosis show no clinically meaningful or statistically significant differences Source text for Eikon: Further company coverage:
June 26th, 2017 | 19:46 PM healthcare 336
Innate Immunotherapeutics Ltd
* Results for trial of MIS416 in patients with secondary progressive multiple sclerosis show no clinically meaningful or statistically significant differences Source text for Eikon: Further company coverage: